Around 750 Volunteers given Covaxin 1st dose in phase-3 trial

Around 750 volunteers have been given first dose of ‘Covaxin’ as part of its phase-3 trails at a city hospital and none of them have experienced any kind of side effects so far. The Bharat Biotech firm is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).

An official said “Over 750 volunteers, including around 50 health workers like doctors, nursing staff, para-medics, have been administered the first dose of Covaxin since its phase-3 trial began on November 25. None of the volunteers have experienced any kind of side effects so far.”

The first dose of the Covaxin is given after the mandatory RT-PCR test. However, for the second booster dose, no such test is required when the vaccine is administered.





Leave A Reply

Your email address will not be published.